Brain Trauma Research
C. Edward Dixon, PhD, directs the Department of Neurological Surgery’s Brain Trauma Research Center (BTRC) at the University of Pittsburgh. The BTRC is a multidisciplinary, multidepartmental research program aimed at improving outcome following severe traumatic brain injury. Research conducted both at our Center and at other brain injury research programs clearly demonstrates the potential for improving outcomes using therapies designed to treat biochemical derangements that occur following impact to the brain. In order to identify the most critical of these sequelae of brain injury and to find newer therapies that are effective in treating them, the BTRC has established several basic science head injury laboratories and clinical research projects.
Neurotrauma Clinical Trials Center
David O. Okonkwo, MD, PhD, leads the department’s efforts in clinical neurotrauma research. The clinical brain injury research is wide spanning and includes the conduct of clinical trials funded by the federal agencies and industry to study new therapies, novel brain monitoring, neuroimaging and biomarkers. The Department of Neurological Surgery has pioneered efforts using hypothermia and cerebral blood flow monitoring in the treatment of severe head injury and has conducted landmark investigations into the mechanisms of induction and recovery of head trauma and secondary injury. For more information on our trials, please visit our Clinical Trials page.
Safar Center for Resuscitation Research
TheThe Safar Center for Resuscitation Research is directed by Patrick Kochanek, MD, of the Department of Critical Care, and has a strong collaborative and productive relationship with several members of the Brain Trauma Research Center. Neurosurgical faculty Dr. Dixon and Larry W. Jenkins, PhD, serve as associate directors of the Safar Center. This facility includes basic science laboratories directed by Drs. Dixon and Jenkins. The mission of the Safar Center is to improve understanding of the mechanisms of secondary injury after traumatic brain injury, cardiopulmonary arrest, severe hemorrhage from whatever cause, and to contribute to the development and implementation of novel and increasingly more effective therapies.